An observational study in Acute Lymphoblastic Leukemia, sponsored by Versailles Hospital. Recruiting at 23 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Versailles Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France — 29 open to participants now, 40 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · France.
Among the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France, this one is the 17th largest by planned enrollment of the 35 observational ones that give a count, is one of 3 that started in 2024, is one of 35 observational ones, reaches primary completion later than 15 of the 39 other live ones, and was the 151st registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →29 of the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, Australia, Israel and 3 more countries
Ages 1–30
Nantes University Hospital · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 18 · Healthy volunteers
Bambino Gesù Hospital and Research Institute · Sites in France, Austria, Czechia and 6 more countries
Ages 3 mo–25 yrs
Princess Maxima Center for Pediatric Oncology · Sites in France, Austria, Belgium and 11 more countries
Ages 1–21
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 62 · Phase 3 33 · Phase 4 2
First in 1994; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 96 across the 115 interventional studies, 100 across the 35 observational. Of the 88 that completed or were terminated, 32 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 152 have an industry lead sponsor. The 10 most frequent:
Versailles Hospital is the lead sponsor of 74 studies on the registry; 16 are open to participants now.
Versailles Hospital has 5 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
11 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT06350994Assistance Publique - Hôpitaux de ParisEarly Assessment of Cardiac Function After Treatment With CAR-T Cells | 2026-12 |
| NCT05310591Assistance Publique - Hôpitaux de ParisCombination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | 2027-03 |
| NCT06867289Centre Hospitalier Régional Metz-ThionvilleStudy of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring | 2027-04-08 |
Add all 11 to your calendar (.ics) → With an account.
Among the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Overall survival by 12 months
Time frame: 12 months
overal survival by 36 months
Time frame: 36 months
proportion of complete remission
Time frame: 36 months
the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood
Time frame: 36 months
the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood
Time frame: 36 months
Event free survival
Time frame: 36 months
Relapse free survival
Time frame: 36 months
the incidence ofBCR..ABL1 TK mutations
Time frame: 36 months
treatment tolerance
Time frame: 36 months
Death during induction
Time frame: 2 months
Death in complete remission
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.
Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 41 months is below that.
Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Versailles Hospital